Not Yet RecruitingNCT07434973
Stratification and Treatment in Early Psychosis Study - PROMOTE
Medication studyAges 12–35Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 12 years to 35 years.
- Listed locations
- Vienna and 18 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: December 1, 2026
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 586
- Sponsor
- University of Oxford
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada, United Kingdom, Switzerland, ...
- Age range
- From 12 Years to 35 Years
- Official registry ID
- NCT07434973
- Official title
Show the full official title
ImPRoving OutcoMes in Individuals at Clinical High Risk fOr Psychosis Using Cannabidiol: a Double-blind, Randomised conTrollEd Trial
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vienna, Austria · Montreal, Canada · Turku, Finland
16 more locations
- Berlin, Germany
- Cologne, Germany
- Lübeck, Germany
- München, Germany
- Athens, Greece
- Bari, Italy
- Naples, Italy
- Pavia, Italy
- Roma, Italy
- Amsterdam, Netherlands
- Bilbao, Spain
- Madrid, Spain
- Zurich, Switzerland
- Cambridge, United Kingdom
- London, United Kingdom
- Oxford, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Oxford, a university.
Does this study involve medication?
Yes. The study involves medication, including Cannabidiol (CBD) and Placebo.
Who can participate?
Listed age limits: 12 years to 35 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
